American Journal of Ophthalmology
Volume 133, Issue 2 , Pages 242-248 , February 2002

Altered expression of rb and p53 in uveal melanomas following plaque radiotherapy1

  • Milam A Brantley Jr, MD, PhD

      Affiliations

    • Center for Ocular Oncology, Department of Ophthalmology and Visual Sciences and Division of Molecular Oncology, Washington University School of Medicine, St. Louis, Missouri USA
    • ,
  • Lori Worley, BS

      Affiliations

    • Center for Ocular Oncology, Department of Ophthalmology and Visual Sciences and Division of Molecular Oncology, Washington University School of Medicine, St. Louis, Missouri USA
    • ,
  • J.William Harbour, MD

      Affiliations

    • Center for Ocular Oncology, Department of Ophthalmology and Visual Sciences and Division of Molecular Oncology, Washington University School of Medicine, St. Louis, Missouri USA
    • Corresponding Author InformationAddress reprint requests to J. William Harbour, MD, Washington University, Box 8069, 660 S. Euclid Ave., St. Louis, MO 63110 USA

,Accepted 9 April 2001.

References 

  1. Diener-West M, Earle JD, Fine SL, Hawkins BS, Moy CS, Reynolds SM, et al. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma. III (Initial mortality findings. COMS Report No. 18). Arch Ophthalmol. 2001;119:969–982
  2. Packer S, Stoller S, Lesser ML, Mandel FS, Finger PT. Long-term results of iodine 125 irradiation of uveal melanoma. Ophthalmology. 1992;99:767–773
  3. Quivey JM, Augsburger J, Snelling L, Brady LW. 125I plaque therapy for uveal melanoma. Analysis of the impact of time and dose factors on local control. Cancer. 1996;77:2356–2362
  4. Garretson BR, Robertson DM, Earle JD. Choroidal melanoma treatment with iodine 125 brachytherapy. Arch Ophthalmol. 1987;105:1394–1397
  5. Karlsson UL, Augsburger JJ, Shields JA, Markoe AM, Brady LW, Woodleigh R. Recurrence of posterior uveal melanoma after 60Co episcleral plaque therapy. Ophthalmology. 1989;96:382–388
  6. Vrabec TR, Augsburger JJ, Gamel JW, Brady LW, Hernandez C, Woodleigh R. Impact of local tumor relapse on patient survival after cobalt 60 plaque radiotherapy. Ophthalmology. 1991;98:984–988
  7. Gragoudas ES, Egan KM, Seddon JM, Walsh SM, Munzenrider JE. Intraocular recurrence of uveal melanoma after proton beam irradiation. Ophthalmology. 1992;99:760–766
  8. Harbour JW, Char DH, Kroll S, Quivey JM, Castro J. Metastatic risk for distinct patterns of post-irradiation local recurrence of posterior uveal melanoma. Ophthalmology. 1997;104:1785–1792
  9. Egger E, Schalenbourg A, Zografos L, Bercher L, Boehringer T, Chamot L, et al. Maximizing local tumor control and survival after proton beam radiotherapy of uveal melanoma. Int J Radiat Oncol Biol Phys. 2001;51:138–147
  10. Thompson LH, Suit HD. Proliferation kinetics of x-irradiated mouse L cells studied with time-lapse photography. I. Experimental methods and data analysis. Int J Radiat Biol Relat Stud Phys Chem Med. 1967;13:391–397
  11. Coleman CN, Beard CJ, Hlatky L, Kwok TT, Bump E. Biochemical modifier (hypoxic cell sensitizers). In:  Mauch PM,  Loeffler JS editor. Radiation oncology (Technology and biology). Philadelphia: W.B. Saunders; 1994;p. 56–89
  12. Yarnold J. Molecular aspects of cellular responses to radiotherapy. Radiother Oncol. 1997;44:1–7
  13. Kao GD, McKenna WG. Genetics of radiation resistance. In:  Mauch PM,  Loeffler JS editor. Radiation Oncology (Technology and Biology). Philadelphia: W.B. Saunders; 1994;p. 442–455
  14. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 1991;51:6304–6311
  15. Vogelstein B, Kinzler KW. p53 function and dysfunction. Cell. 1992;70:523–526
  16. Flatt PM, Tang LJ, Scatena CD, Szak ST, Pietenpol JA. p53 regulation of G(2) checkpoint is retinoblastoma protein dependent. Mol Cell Biol. 2000;20:4210–4223
  17. Brugarolas J, Moberg K, Boyd SD, Taya Y, Jacks T, Lees JA. Inhibition of cyclin-dependent kinase 2 by p21 is necessary for retinoblastoma protein-mediated G1 arrest after gamma-irradiation. Proc Natl Acad Sci USA. 1999;96:1002–1007
  18. Harrington EA, Bruce JL, Harlow E, Dyson N. pRB plays an essential role in cell cycle arrest induced by DNA damage. Proc Natl Acad Sci USA. 1998;95:11945–11950
  19. Brantley MA, Harbour JW. Deregulation of the Rb and p53 pathways in uveal melanoma. Am J Pathol. 2000;157:1795–1801
  20. Char DH, Huhta K, Waldman F. DNA cell cycle studies in uveal melanoma. Am J Ophthalmol. 1989;107:65–72
  21. Kenneally CZ, Farber MG, Smith ME, Devineni R. In vitro melanoma cell growth after pre-enucleation radiation therapy. Arch Ophthalmol. 1988;106:223–224
  22. Rousseau AP, Deschenes J, Pelletier G, Tremblay M, Larochelle-Belland M. Effect of pre-enucleation radiotherapy on the viability of human choroidal melanoma cells. Can J Ophthalmol. 1989;24:10–14
  23. COMS report no. 6 . Histopathologic characteristics of uveal melanomas in eyes enucleated from the Collaborative Ocular Melanoma Study. Am J Ophthalmol. 1998;125:745–766
  24. Shields CL, Shields JA, Karlsson U, Menduke H, Brady LW. Enucleation after plaque radiotherapy for posterior uveal melanoma. Histopathologic findings. Ophthalmology. 1990;97:1665–1670
  25. Char DH, Crawford JB, Kaleta-Michaels S, Howes EL, Lovato AA, Quivey JM. Analysis of radiation failure after uveal melanoma brachytherapy. Am J Ophthalmol. 1989;108:712–716
  26. Schilling H, Sehu KW, Lee WR. A histologic study (including DNA quantification and Ki-67 labeling index) in uveal melanomas after brachytherapy with ruthenium plaques. Invest Ophthalmol Vis Sci. 1997;38:2081–2092
  27. Seregard S, Lundell G, Lax I, af Trampe E, Kock E. Tumour cell proliferation after failed ruthenium plaque radiotherapy for posterior uveal melanoma. Acta Ophthalmol Scand. 1997;75:148–154
  28. Carrano AV. Chromosome aberrations and radiation-induced cell death. II. Predicted and observed cell survival. Mutat Res. 1973;17:355–366
  29. Cornforth MN, Bedford JS. X-ray-induced breakage and rejoining of human interphase chromosomes. Science. 1983;222:1141–1143
  30. Horsman DE, White VA. Cytogenetic analysis of uveal melanoma. Consistent occurrence of monosomy 3 and trisomy 8q. Cancer. 1993;71:811–819
  31. Sisley K, Rennie IG, Parsons MA, Jacques R, Hammond DW, Bell SM, et al. Abnormalities of chromosomes 3 and 8 in posterior uveal melanoma correlate with prognosis. Genes Chromosomes Cancer. 1997;19:22–28
  32. Prescher G, Bornfeld N, Friedrichs W, Seeber S, Becher R. Cytogenetics of twelve cases of uveal melanoma and patterns of nonrandom anomalies and isochromosome formation. Cancer Genet Cytogenet. 1995;80:40–46
  33. Janssen K, Kuntze J, Busse H, Schmid KW. p53 oncoprotein overexpression in choroidal melanoma. Mod Pathol. 1996;9:267–272
  34. Jay V, Yi Q, Hunter WS, Zielenska M. p53 expression in uveal malignant melanomas. Pathology. 1996;28:306–308
  35. Kishore K, Ghazvini S, Char DH, Kroll S, Selle J. p53 gene and cell cycling in uveal melanoma. Am J Ophthalmol. 1996;121:561–567
  36. Tobal K, Warren W, Cooper CS, McCartney A, Hungerford J, Lightman S. Increased expression and mutation of p53 in choroidal melanoma. Br J Cancer. 1992;66:900–904
  37. Massaro-Giordano M, Baldi G, De Luca A, Baldi A, Giordano A. Differential expression of the retinoblastoma gene family members in choroidal melanoma (Prognostic significance). Clin Cancer Res. 1999;5:1455–1458
  38. Coupland SE, Bechrakis N, Schuler A, Anagnostopoulos I, Hummel M, Bornfeld N, et al. Expression patterns of cyclin D1 and related proteins regulating G1-S phase transition in uveal melanoma and retinoblastoma. Br J Ophthalmol. 1998;82:961–970
  39. Chana JS, Wilson GD, Cree IA, Alexander RA, Myatt N, Neale M, et al. c-myc, p53, and Bcl-2 expression and clinical outcome in uveal melanoma. Br J Ophthalmol. 1999;83:110–114
  40. Prives C, Hall PA. The p53 pathway. J Pathol. 1999;187:112–126
  41. Zacksenhaus E, Bremner R, Phillips RA, Gallie BL. A bipartite nuclear localization signal in the retinoblastoma gene product and its importance for biological activity. Mol Cell Biol. 1993;13:4588–4599
  42. Dou QP, An B. RB and apoptotic cell death. Front Biosci 1998:419–430.

☆ This work was supported by NIH grants K08 EY00382-01 and R01 EY13169-01. Dr. Harbour was supported by a Career Development Award from Research to Prevent Blindness, Inc.

PII: S0002-9394(01)01362-9

American Journal of Ophthalmology
Volume 133, Issue 2 , Pages 242-248 , February 2002

Article Tools

* Image Usage & Resolution